Batoclimab vs Placebo for Generalized Myasthenia Gravis
JAMA Neurology · 01.04.2024 · 81 (4) · 336
DOI: 10.1001/jamaneurol.2024.0044 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Neurology, erschienen am 01.04.2024. Verfasst von Chong Yan und 33 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Neurological Disorders, Huashan Rare Disease Centre, Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Myasthenia gravis (MG) is caused by autoantibodies that disrupt the neuromuscular junction. The neonatal fragment crystallizable receptor (FcRn) antagonists, efgartigimod and rozanolixizumab, reduce immunoglobulin G (IgG) level in the circulation and alleviate symptoms in patients with generalized MG.
Objective
To examine the efficacy and safety profile of batoclimab, a monoclonal IgG1 antibody, in patients with generalized MG. Design, Setting, and Participants This was a multicenter randomized clinical trial conducted from September 15, 2021, to June 29, 2022, at 27 centers in China. Adult patients 18 years or older with generalized MG were screened, and those who were antibody positive were enrolled.
Intervention
Eligible patients received batoclimab or matching placebo in addition to standard of care. Each treatment cycle consisted of 6 weekly subcutaneous injections of batoclimab, 680 mg, or matching placebo followed by 4 weeks of observation. A second treatment cycle was conducted in patients who required continuing treatment. Main Outcome and Measure The primary outcome was sustained improvement, as defined by a 3-point or greater reduction in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline for 4 or more consecutive weeks in the first cycle in individuals who were positive for acetylcholine receptor or muscle-specific kinase antibodies.
Results
A total of 178 adult patients with generalized MG were screened, 132 were randomly assigned, 131 tested positive for antibodies, and 1 tested negative for antibodies. A total of 132 patients (mean [SE] age, 43.8 [13.6] years; 88 women [67.2%]) were enrolled. The rate of sustained MG-ADL improvement in the first cycle in antibody-positive patients was 31.3% (20 of 64) in the placebo group vs 58.2% (39 of 67) in the batoclimab group (odds ratio, 3.45; 95% CI, 1.62-7.35; P = .001). The MG-ADL score diverged between the 2 groups as early as week 2. The mean (SE) maximum difference in MG-ADL score reduction occurred 1 week after the last dose (day 43, 1.7 [0.3] in the placebo group vs 3.6 [0.3] in the batoclimab group; group difference, −1.9; 95% CI, −2.8 to −1.0; nominal P < .001). The rates of treatment-related and severe treatment-emergent adverse events in patients were 36.9% (24 of 65) and 7.7% (5 of 65) in the placebo group vs 70.1% (47 of 67) and 3.0% (2 of 67) in the batoclimab group, respectively. Conclusions and Relevance Batoclimab increased the rate of sustained MG-ADL improvement and was well tolerated in adult patients with generalized MG. Clinical effects and the extent of IgG reduction were similar to those previously reported for efgartigimod and rozanolixizumab. Future studies of large sample size are needed to further understand the safety profile of batoclimab. Trial Registration ClinicalTrials.gov Identifier: NCT05039190
Autor:innen und Institutionen
- National Center for Neurological Disorders, Huashan Rare Disease Centre, Department of Neurology, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Neurology, Qilu Hospital (Qingdao), Shandong University, Qingdao, China.
- Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Neurology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Neurology, the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Ji'nan, China.
Zitieren
APA
Yan, C., Yue, Y., Guan, Y., Bu, B., Ke, Q., Duan, R., Deng, H., Xue, Q., Jiang, H., Xiao, F., Yang, H., Chang, T., Zou, Z., Li, H., Tan, S., Xiao, H., Zhou, H., Zhang, H., Meng, Q., …, & Batoclimab Study Team (2024). Batoclimab vs Placebo for Generalized Myasthenia Gravis. JAMA Neurology, 81(4), 336. https://doi.org/10.1001/jamaneurol.2024.0044
Vancouver
Yan C, Yue Y, Guan Y, Bu B, Ke Q, Duan R, et al. Batoclimab vs Placebo for Generalized Myasthenia Gravis. JAMA Neurology. 2024;81(4):336. doi:10.1001/jamaneurol.2024.0044
BibTeX
@article{Yan2024,
author = {Yan, Chong and Yue, Yaoxian and Guan, Yuzhou and Bu, Bitao and Ke, Qing and Duan, Ruisheng and Deng, Hui and Xue, Qun and Jiang, Haishan and Xiao, Fei and Yang, Huan and Chang, Ting and Zou, Zhangyu and Li, Haifeng and Tan, Song and Xiao, Haibing and Zhou, Hongyu and Zhang, Hua and Meng, Qiang and Li, Wenyu and Li, Wei and Guo, Junhong and Zhang, Yali and Li, Zunbo and Tu, Jianglong and Shi, Jianquan and Li, Wei and Lee, Michael and Chen, Yu and Tao, Xiaolu and Zhao, Shuai and Li, Ping and Zhao, Chongbo and Batoclimab Study Team, Batoclimab Study Team},
title = {Batoclimab vs Placebo for Generalized Myasthenia Gravis},
journal = {JAMA Neurology},
year = {2024},
volume = {81},
number = {4},
pages = {336},
doi = {10.1001/jamaneurol.2024.0044}
}
EUVIMED